MassMutual Private Wealth & Trust FSB Has $71,000 Holdings in Illumina, Inc. (NASDAQ:ILMN)

MassMutual Private Wealth & Trust FSB raised its position in Illumina, Inc. (NASDAQ:ILMN) by 25.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 535 shares of the life sciences company’s stock after purchasing an additional 109 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in Illumina were worth $71,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Versant Capital Management Inc raised its position in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares during the last quarter. TD Private Client Wealth LLC grew its stake in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after acquiring an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its holdings in shares of Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after purchasing an additional 168 shares during the last quarter. Private Trust Co. NA raised its holdings in shares of Illumina by 81.2% in the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after purchasing an additional 212 shares during the last quarter. Finally, Focused Wealth Management Inc bought a new stake in shares of Illumina in the third quarter worth $63,000. 89.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Canaccord Genuity Group lifted their target price on Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research report on Tuesday, November 5th. Hsbc Global Res upgraded Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price target for the company in a research note on Thursday, October 17th. Stephens boosted their price target on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Finally, Robert W. Baird increased their price objective on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $165.63.

Illumina Stock Down 4.0 %

ILMN stock opened at $134.76 on Friday. The business’s fifty day moving average price is $139.06 and its two-hundred day moving average price is $134.26. The stock has a market capitalization of $21.37 billion, a price-to-earnings ratio of -13.53 and a beta of 1.11. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter in the previous year, the company earned $0.33 EPS. The business’s revenue was down 3.5% on a year-over-year basis. On average, equities analysts anticipate that Illumina, Inc. will post 4.13 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.